Search

Your search keyword '"Mycoses -- Care and treatment -- Health aspects"' showing total 116 results
Start Over Descriptor "Mycoses -- Care and treatment -- Health aspects"
116 results on '"Mycoses -- Care and treatment -- Health aspects"'

1. Scynexis announces positive interim data from phase 3 FURI and CARES studies of ibrexafungerp to treat severe fungal infections

Subjects
Care and treatment, Health aspects, Product development, Mycoses -- Care and treatment -- Health aspects, Microbial drug resistance -- Care and treatment -- Health aspects, Antifungal agents -- Product development -- Health aspects, Drug resistance in microorganisms -- Care and treatment -- Health aspects
Abstract

Scynexis, Inc., a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, announced positive interim data from its ongoing phase 3 FURI and CARES studies. 'These [...]

Published
2022

2. Data from University of Bologna Advance Knowledge in Mycoses (Saprochaete Clavata Infections In Patients Undergoing Treatment for Haematological Malignancies: a Report of a Monocentric Outbreak and Review of the Literature)

Subjects
University of Bologna, Care and treatment, Health aspects, Physical fitness -- Health aspects, Mycoses -- Care and treatment -- Health aspects, Cancer -- Care and treatment -- Health aspects, Infection -- Care and treatment -- Health aspects, Mortality, Obesity, Voriconazole, Editors, Social science research
Abstract

2019 NOV 16 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Life Science Research - Mycoses have been published. [...]

Published
2019

3. Regulatory oversight and safety of probiotic use

Author

Venugopalan, Veena, Shriner, Kimberly A., and Wong-Beringer, Annie

Subjects
United States. Food and Drug Administration, Care and treatment, Health aspects, Mycoses -- Care and treatment -- Health aspects, Safety regulations -- Health aspects, Infection -- Care and treatment -- Health aspects, Probiotics -- Health aspects, Dietary supplements -- Health aspects
Abstract

Probiotics are defined by the Food and Agriculture Organization of the World Health Organization as live microorganisms that, when administered in adequate amounts, confer a health benefit on the host [...]

Published
2010
Full Text
View/download PDF

4. Fungal infections might be dangerous to Covid-19 patients with severe symptoms in ICU

Subjects
Mycoses -- Care and treatment -- Health aspects, Infection -- Care and treatment -- Health aspects, Business, international
Abstract

Summary: Covid-19 patients with severe symptoms who end up in intensive care units in hospitals are at risk of contracting an invasive fungal infection that might influence their outcomes and [...]

Published
2021

5. Investigators from National Institutes of Health Zero in on Hydrocephalus (Endoscopic ventriculo-cisterno-ventricular approach in the treatment of bilateral trapped temporal horn related to fungal infection in a child: case report and review of ...)

Subjects
United States. National Institutes of Health, Care and treatment, Health aspects, Physical fitness -- Health aspects, Mycoses -- Care and treatment -- Health aspects, Nervous system diseases -- Care and treatment -- Health aspects, Hydrocephalus -- Care and treatment -- Health aspects
Abstract

2018 AUG 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New research on Central Nervous System Diseases and Conditions - Hydrocephalus is [...]

Published
2018

6. New Nitric Oxide Data Have Been Reported by N. Stasko and Co-Authors (Nitric Oxide-Releasing Macromolecule Exhibits Broad-Spectrum Antifungal Activity and Utility as a Topical Treatment for Superficial Fungal Infections)

Subjects
Exhibitions, Care and treatment, Health aspects, Physical fitness -- Health aspects, Mycoses -- Care and treatment -- Health aspects, Antifungal agents -- Exhibitions -- Health aspects, Nitric oxide -- Exhibitions -- Health aspects, Infection -- Care and treatment -- Health aspects
Abstract

2018 JUL 28 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Nitrogen Oxides - Nitric Oxide. According to [...]

Published
2018

7. SCYNEXIS Reports Full Year 2019 Financial Results and Provides Company Update

Subjects
United States. Food and Drug Administration -- Officials and employees, Mycoses -- Care and treatment -- Health aspects, Infection -- Care and treatment -- Health aspects, Vulvovaginal candidiasis, Finance, Candidiasis, Banking, finance and accounting industries, Business
Abstract

JERSEY CITY, Mar 11, 2020 (GLOBE NEWSWIRE via COMTEX) -- -- Nearing completion of Phase 3 VANISH program, evaluating oral ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC), more commonly [...]

Published
2020

8. New Findings from University Hospital in the Area of Liposomes Reported (Nebulized Liposomal Amphotericin B for Treatment of Pulmonary Infection Caused by Hormographiella aspergillata: Case Report and Literature Review)

Subjects
Care and treatment, Health aspects, Physical fitness -- Health aspects, Mycoses -- Care and treatment -- Health aspects, Antiparasitic agents -- Health aspects, Hematopoietic stem cells -- Health aspects, Respiratory system agents -- Health aspects, Infection -- Care and treatment -- Health aspects, Lung diseases -- Care and treatment -- Health aspects, Hematopoietic stem cell transplantation -- Health aspects, Amphotericin B -- Health aspects
Abstract

2017 AUG 5 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on Biotechnology - Liposomes are discussed in a new report. [...]

Published
2017

9. Pfizer obtains exclusive commercialization rights in Europe to Cresemba from Basilea Pharma to treat fungal infections among immunocompromised patients

Subjects
Pfizer Inc. -- Licensing agreements, Cresemba (Medication) -- Health aspects, Care and treatment, Licensing agreements, Health aspects, Company licensing agreement, Immunocompromised host -- Care and treatment -- Health aspects, Mycoses -- Care and treatment -- Health aspects, Antifungal agents -- Licensing agreements -- Health aspects, Infection -- Care and treatment -- Health aspects, Pharmaceutical industry -- Licensing agreements -- Health aspects
Abstract

Pfizer Inc. and Basilea Pharmaceutica Ltd., an international biopharmaceutical company specializing in the research and development of anti-infective and oncological medicines, announced they have completed the licensing agreement whereby Pfizer [...]

Published
2017

10. Pfizer Receives Exclusive Commercialization Rights in Europe for CRESEMBA, a Novel Treatment for Potentially Life-Threatening Fungal Infections Among Immunocompromised Patients

Subjects
Pfizer Inc., Cresemba (Medication) -- Health aspects, Care and treatment, Health aspects, Research and development, Immunocompromised host -- Care and treatment -- Health aspects, Physical fitness -- Health aspects, Mycoses -- Care and treatment -- Health aspects, Antifungal agents -- Health aspects, Infection -- Care and treatment -- Health aspects, Industrial research -- United States -- Health aspects, Pharmaceutical industry -- Health aspects
Abstract

2017 JUL 1 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Pfizer Inc. (NYSE: PFE)and Basilea Pharmaceutica Ltd. (SIX:BSLN), an international biopharmaceutical company [...]

Published
2017

11. Reports from Complutense University Advance Knowledge in Macrolides (Unmet clinical needs in the treatment of systemic fungal infections: The role of amphotericin B and drug targeting)

Subjects
Care and treatment, Health aspects, Physical fitness -- Health aspects, Mycoses -- Care and treatment -- Health aspects, Antiparasitic agents -- Health aspects, Infection -- Care and treatment -- Health aspects, Amphotericin B -- Health aspects
Abstract

2017 JUN 10 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on Macrolides is now available. According to news reporting [...]

Published
2017

12. New Hematology Research Findings from L. Pagano and Co-Researchers Described (Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations)

Subjects
Care and treatment, Health aspects, Physical fitness -- Health aspects, Mycoses -- Care and treatment -- Health aspects, Cancer -- Care and treatment -- Health aspects, Infection -- Care and treatment -- Health aspects, Hematopoietic stem cell transplantation -- Health aspects
Abstract

2017 MAY 27 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on Health and Medicine - Hematology Research are presented in [...]

Published
2017

13. Mold contributes to death of COVID-19 Patients, Reports DryMore

Subjects
Care and treatment, Death of, Health aspects, Mycoses -- Care and treatment -- Health aspects, COVID-19 -- Care and treatment -- Health aspects
Abstract

2021 NOV 2 (NewsRx) -- By a News Reporter-Staff News Editor at Virus Weekly -- Evidence is mounting that Aspergillus, a common group of fungi found in high concentrations in [...]

Published
2021

14. Fungal contamination of methylprednisolone causing recurrent lumbosacral intradural abscess

Author

Renfrow, Jaclyn J., Frenkel, Mark B., and Hsu, Wesley

Subjects
United States. Centers for Disease Control and Prevention, Care and treatment, Contamination, Health aspects, Mycoses -- Care and treatment -- Health aspects, Meningitis -- Care and treatment -- Health aspects, Recurrence (Disease) -- Care and treatment -- Health aspects, Steroids (Organic compounds) -- Health aspects, Antifungal agents -- Contamination -- Health aspects, Long term care -- Health aspects, Glucocorticoids -- Contamination -- Health aspects, Methylprednisolone -- Contamination -- Health aspects
Abstract

Fungal meningitis transmitted through injections of methylprednisolone contaminated with Exserohilum rostratum affected 753 persons and caused 61 deaths in the United States in 2012 (1). More than 13,400 patients were [...]

Published
2017

15. Reports from Statens Serum Institute Add New Data to Findings in Antifungals (Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the ...)

Subjects
Care and treatment, Usage, Health aspects, Physical fitness -- Health aspects, Mycoses -- Care and treatment -- Health aspects, Molds (Fungi) -- Health aspects, Antifungal agents -- Usage -- Health aspects, Drug resistance -- Care and treatment -- Health aspects, Epidemiology -- Health aspects
Abstract

2017 JAN 14 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Drugs and Therapies - Antifungals have been published. [...]

Published
2017

16. Researchers at Duke University Hospital Target Candida (Role of isavuconazole in the treatment of invasive fungal infections)

Subjects
Care and treatment, Health aspects, Physical fitness -- Health aspects, Mycoses -- Care and treatment -- Health aspects, Antifungal agents -- Health aspects, Infection -- Care and treatment -- Health aspects, Triazoles -- Health aspects
Abstract

2016 SEP 10 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Fungal Diseases and Conditions - Candida. According [...]

Published
2016

17. Studies from Catalan Institute of Oncology Have Provided New Data on Neutropenia (Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?)

Subjects
Care and treatment, Health aspects, Prophylaxis -- Health aspects, Physical fitness -- Health aspects, Mycoses -- Care and treatment -- Health aspects, Antifungal agents -- Health aspects, Medical research -- Health aspects, Antineoplastic agents -- Health aspects
Abstract

2016 AUG 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Leukocyte Disorders. According to news originating from [...]

Published
2016

18. SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting

Subjects
Mycoses -- Care and treatment -- Health aspects, Antifungal agents -- Health aspects, Infection -- Care and treatment -- Health aspects, Biotechnology industries, Novels, General interest, News, opinion and commentary
Abstract

JERSEY CITY: SCYNEXIS, Inc. has issued the following press release: SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced positive results [...]

Published
2020

19. SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting

Subjects
Mycoses -- Care and treatment -- Health aspects, Infection -- Care and treatment -- Health aspects, Antifungal agents -- Health aspects, Business, News, opinion and commentary
Abstract

Consistent with the first interim analysis, results confirm clinical antifungal activity of oral ibrexafungerp in patients with difficult-to-treat, severe, mucocutaneous and invasive fungal infections, including those caused by resistant strains [...]

Published
2020

20. Probiotic Yeast May Offer an Effective Treatment for Drug-Resistant Fungal Infections

Subjects
Mycoses -- Care and treatment -- Health aspects, Antifungal agents -- Health aspects, Drug resistance -- Care and treatment -- Health aspects, Infection -- Care and treatment -- Health aspects, Project-based learning -- Health aspects, Catalogs, College students, Technical institutes, Education, News, opinion and commentary, Sports and fitness, Worcester Polytechnic Institute
Abstract

Probiotic Yeasts May Treat Drug- Resistant Fungal Infections Skip to main content Menu .st0{fill:#FFFFFF;} Worcester Polytechnic Institute Worcester Polytechnic Institute short form logo .st0{fill:#FFFFFF;} Worcester Polytechnic Institute Worcester Polytechnic Institute [...]

Published
2019

21. SCYNEXIS Expands FURI Protocol to a Broader Range of Refractory Serious Fungal Infections, Building on Ibrexafungerp's Positive Data and Favorable Toxicology Profile Observed to Date

Subjects
Mycoses -- Care and treatment -- Health aspects, Antifungal agents -- Health aspects, Infection -- Care and treatment -- Health aspects, Biotechnology industries, Novels, General interest, News, opinion and commentary
Abstract

JERSEY CITY: SCYNEXIS, Inc. has issued the following press release: SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced an amendment to [...]

Published
2019

22. SCYNEXIS Expands FURI Protocol to a Broader Range of Refractory Serious Fungal Infections, Building on Ibrexafungerp's Positive Data and Favorable Toxicology Profile Observed to Date

Subjects
Mycoses -- Care and treatment -- Health aspects, Infection -- Care and treatment -- Health aspects, Antifungal agents -- Health aspects, Business, News, opinion and commentary
Abstract

Use of oral ibrexafungerp expanded to patients with aspergillosis, coccidioidomycosis, histoplasmosis, blastomycosis and other emerging, difficult-to-treat fungal infections Maximum allowed treatment duration increased to six months based on favorable preclinical [...]

Published
2019

23. John Spellar ask the Secretary of State for Health and Social Care, what recent assessment he has made of the risks to patient health posed by fungal infections; and what steps he is taking to tackle those risks

Subjects
Mycoses -- Care and treatment -- Health aspects, Infection -- Care and treatment -- Health aspects, Aspergillosis, Therapeutics, Public health, Business, international
Abstract

London: United Kingdom House of Commons has issued the following written answer: Answered by: Seema Kennedy Answered on: 20 June 2019 The most common invasive fungal infection in the United [...]

Published
2019

24. SCYNEXIS Reports Full Year 2018 Financial Results and Provides Company Update

Subjects
United States. Food and Drug Administration, Mycoses -- Care and treatment -- Health aspects, Infection -- Care and treatment -- Health aspects, Convertible securities -- Health aspects, Airports -- Runways, Company earnings/profit, Business, News, opinion and commentary
Abstract

Phase 3 VANISH program underway, evaluating oral ibrexafungerp for the treatment of acute VVC; anticipate top-line data in the first half of 2020 with NDA submission in the second half [...]

Published
2019

25. F2G wins US FDA ODD for Olorofim for treating life-threatening fungal infections

Subjects
United States. Food and Drug Administration, F2G Ltd., Mycoses -- Care and treatment -- Health aspects, Antifungal agents -- Health aspects, Infection -- Care and treatment -- Health aspects, Aspergillosis, Biotechnology, Biotechnology industries, Orphan drugs, Chemistry
Abstract

M2 PHARMA-March 10, 2020-F2G wins US FDA ODD for Olorofim for treating life-threatening fungal infections (C)2020 M2 COMMUNICATIONS F2G Ltd revealed on Monday the receipt of US Food and Drug [...]

Published
2020

26. F2G wins US FDA ODD for Olorofim for treating life-threatening fungal infections

Subjects
United States. Food and Drug Administration, F2G Ltd., Mycoses -- Care and treatment -- Health aspects, Antifungal agents -- Health aspects, Infection -- Care and treatment -- Health aspects, Aspergillosis, Biotechnology, Biotechnology industries, Orphan drugs, Business
Abstract

M2 EQUITYBITES-March 10, 2020-F2G wins US FDA ODD for Olorofim for treating life-threatening fungal infections (C)2020 M2 COMMUNICATIONS http://www.m2.com F2G Ltd revealed on Monday the receipt of US Food and [...]

Published
2020

27. World's first clinical guidelines for chronic fungal lung infections

Subjects
European Respiratory Society, Care and treatment, Health aspects, Mycoses -- Care and treatment -- Health aspects, Practice guidelines (Medicine) -- Health aspects, Infection -- Care and treatment -- Health aspects, Lung diseases -- Care and treatment -- Health aspects
Abstract

2016 JAN 9 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Switzerland: The world's first guidelines for chronic fungal lung infections for doctors [...]

Published
2016

28. PS24m raised for tackling lung diseases

Subjects
Lung diseases -- Care and treatment -- Health aspects, Mycoses -- Care and treatment -- Health aspects
Abstract

By Julia Bradshaw A SMALL British biotech firm run by a team of former GLAXOSMITHKLINE scientists has raised $30m (PS24.2m) to develop two treatments for deadly viral and fungal lung […]

Published
2017

29. SCYNEXIS Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Oral Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies

Subjects
Antifungal agents -- Product development -- Health aspects, Mycoses -- Care and treatment -- Health aspects, Infection -- Care and treatment -- Health aspects, Biotechnology industries, Retirement benefits, General interest, News, opinion and commentary
Abstract

JERSEY CITY, N.J: SCYNEXIS, Inc. has issued the following press release:SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced positive results [...]

Published
2019

30. SCYNEXIS Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Oral Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies

Subjects
Mycoses -- Care and treatment -- Health aspects, Infection -- Care and treatment -- Health aspects, Business, News, opinion and commentary
Abstract

Analysis of first 20 patients confirms clinical antifungal activity of oral ibrexafungerp in patients with difficult-to-treat mucocutaneous and invasive fungal infections Positive findings support expanding the use of oral ibrexafungerp [...]

Published
2019

31. TOLSURA (TM) (SUBA-itraconazole) Antifungal Capsule Now Available in the United States

Subjects
Respiratory tract diseases -- Care and treatment -- Health aspects, Mycoses -- Care and treatment -- Health aspects, Solifenacin -- Health aspects, Itraconazole -- Health aspects, Business, News, opinion and commentary, Tolsura (Medication) -- Health aspects
Abstract

ADELAIDE, Australia, Jan. 30, 2019 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the launch of TOLSURA(TM) (SUBA-itraconazole) 65mg capsule in the United States. TOLSURA is [...]

Published
2019

32. SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)

Subjects
Mycoses -- Care and treatment -- Health aspects, Antifungal agents -- Health aspects, Infection -- Care and treatment -- Health aspects, General interest, News, opinion and commentary
Abstract

JERSEY CITY: SCYNEXIS, Inc. has issued the following news release: SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the dosing [...]

Published
2018

33. SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)

Subjects
Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Drug resistance in microorganisms -- Care and treatment -- Health aspects, Mycoses -- Care and treatment -- Health aspects, Infection -- Care and treatment -- Health aspects, Antifungal agents -- Health aspects, Clinical trials -- Health aspects, Business, News, opinion and commentary
Abstract

Ibrexafungerp's potent activity against multidrug-resistant fungal pathogen Candida auris confirmed in multiple pre-clinical studies Ibrexafungerp may provide a therapeutic option for this emerging pathogen classified as a serious global health [...]

Published
2018

34. SCYNEXIS Supports AMR Challenge and Fungal Disease Awareness Week

Subjects
United States. Centers for Disease Control and Prevention, United States. Department of Health and Human Services, Drug resistance in microorganisms -- Care and treatment -- Health aspects, Mycoses -- Care and treatment -- Health aspects, Business, News, opinion and commentary
Abstract

-- HHS and CDC Lead Efforts Aim to Combat Antimicrobial Resistance, Raise Awareness of Fungal Diseases -- JERSEY CITY, N.J., Oct. 1, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ : SCYX), [...]

Published
2018

35. SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis

Subjects
United States. Food and Drug Administration, Mycoses -- Care and treatment -- Health aspects, Infection -- Care and treatment -- Health aspects, Antifungal agents -- Product development -- Health aspects, Business, News, opinion and commentary
Abstract

Clinically and mycologically effective and well-tolerated oral dose of SCY-078 identified for use in Phase 3 registration program Results confirm strong clinical activity of oral SCY-078 and suggest improved sustained [...]

Published
2018

36. Drug-filled, 3-D printed dentures could fight off infections

Subjects
Mycoses -- Care and treatment -- Health aspects, Infection -- Care and treatment -- Health aspects, Business, international, State University of New York at Buffalo
Abstract

Nearly two-thirds of the US denture-wearing population suffer frequent fungal infections that cause inflammation, redness and swelling in the mouth. dentures are printed using acrylamide, the current go-to material for [...]

Published
2018

37. Researchers explore little-known, deadly fungal infections

Subjects
Vaccines -- Health aspects, College faculty -- Health aspects, Mycoses -- Care and treatment -- Health aspects, Antifungal agents -- Health aspects, Infection -- Care and treatment -- Health aspects, General interest, News, opinion and commentary
Abstract

Brussels: European AIDS Treatment Group has issued the following press release: A new study by Althea Campuzano, Ph.D. a student at The University of Texas at San Antonio, and Floyd [...]

Published
2018

38. Number of deaths from meningitis due to plummet after new medical advice

Subjects
Mycoses -- Care and treatment -- Health aspects, Meningitis -- Care and treatment -- Health aspects, Virus diseases -- Care and treatment -- Health aspects, Business, international, University of London
Abstract

London : St George's, University of London, United Kingdom has issued the following news release: The fungal infection cryptococcal meningitis is responsible for more than 180,000 deaths per year worldwide, [...]

Published
2018

39. F2G Receives US FDA Breakthrough Therapy Designation for Olorofim

Subjects
United States. Food and Drug Administration, Care and treatment, Health aspects, Mycoses -- Care and treatment -- Health aspects, Antifungal agents -- Health aspects, Aspergillosis, Infection, Biotechnology, Editors, Biotechnology industries, Novels
Abstract

2019 NOV 26 (NewsRx) -- By a News Reporter-Staff News Editor at TB & Outbreaks Week -- F2G Ltd, a UK- and Austria-based biotech company developing novel therapies for life-threatening [...]

Published
2019

40. Recent Findings from All Institute of Medical Sciences Has Provided New Data on Leukemia (Combination antifungals as an effective means of salvage in paediatric leukaemia patients with invasive fungal infections)

Subjects
Care and treatment, Health aspects, Mycoses -- Care and treatment -- Health aspects, Infection -- Care and treatment -- Health aspects, Pediatrics -- Health aspects, Leukemia -- Care and treatment -- Health aspects, Caspofungin -- Health aspects, Mortality, Antifungal agents, Morbidity, Editors
Abstract

2019 SEP 2 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Investigators publish new report on Oncology - Leukemia. According to news reporting originating from New [...]

Published
2019

41. Newly Published Journal of Antimicrobial Chemotherapy Supplement Provides Insights into the Future of Echinocandin Therapy for Invasive Fungal Infections

Subjects
Periodical publishing -- Health aspects, Mycoses -- Care and treatment -- Health aspects, Chemotherapy -- Health aspects, Infection -- Care and treatment -- Health aspects, General interest, News, opinion and commentary
Abstract

San Diego: Cidara Therapeutics, Inc. has issued the following press release: Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that a new compendium of [...]

Published
2018

42. Profile of Peter G. Pappas, M.D., FACP of Matinas Biopharma Holdings, Inc

Subjects
College faculty -- Health aspects, Mycoses -- Care and treatment -- Health aspects, Epidemiology -- Health aspects, Biological products industry -- Health aspects, General interest, News, opinion and commentary
Abstract

New Jersey: Following is the Profile of Peter G. Pappas, M.D., FACP of Matinas Biopharma Holdings, Inc: Dr. Pappas is the William E. Dismukes Professor of Medicine in the Division [...]

Published
2017

43. OPIOID CRISIS LINKED TO RISE IN FUNGAL EYE INFECTIONS, SAY BASCOM PALMER RESEARCHERS

Subjects
Mycoses -- Care and treatment -- Health aspects, Medical research -- Health aspects, Infection -- Care and treatment -- Health aspects, News, opinion and commentary
Abstract

CORAL GABLES, FL -- The following information was released by the University of Miami Miller School of Medicine: A rise in fungal infections of the retina is linked to the [...]

Published
2017

44. 'THINK FUNGUS' - SCYNEXIS Recognizes Fungal Disease Awareness Week Sponsored by the Centers for Disease Control and Prevention (CDC)

Subjects
United States. Centers for Disease Control and Prevention, Mycoses -- Care and treatment -- Health aspects, Health care industry -- Health aspects, Fungi -- Health aspects, Microbial drug resistance -- Care and treatment -- Health aspects, Antifungal agents -- Health aspects, Infection -- Care and treatment -- Health aspects, Health care industry, Banking, finance and accounting industries, Business
Abstract

JERSEY CITY, N.J., Aug 15, 2017 (GLOBE NEWSWIRE via COMTEX) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, commends the Centers [...]

Published
2017

45. Pfizer Receives Exclusive Commercialization Rights in Europe for CRESEMBA, a Novel Treatment for Potentially Life-Threatening Fungal Infections Among Immunocompromised Patients

Subjects
Pfizer Inc., Immunocompromised host -- Care and treatment -- Health aspects, Mycoses -- Care and treatment -- Health aspects, Antifungal agents -- Health aspects, Infection -- Care and treatment -- Health aspects, Industrial research -- United States -- Health aspects, Pharmaceutical industry -- Health aspects, Research and development, General interest, News, opinion and commentary, Cresemba (Medication) -- Health aspects
Abstract

Madrid, Spain: Pfizer has issued the following press release: Pfizer Inc. (NYSE: PFE)and Basilea Pharmaceutica Ltd. (SIX:BSLN), an international biopharmaceutical company specializing in the research and development of anti-infective and [...]

Published
2017

46. Pfizer Receives Exclusive Commercialization Rights in Europe for CRESEMBA, a Novel Treatment for Potentially Life-Threatening Fungal Infections Among Immunocompromised Patients

Subjects
Pfizer Inc., Immunocompromised host -- Care and treatment -- Health aspects, Mycoses -- Care and treatment -- Health aspects, Antifungal agents -- Health aspects, Infection -- Care and treatment -- Health aspects, Industrial research -- United States -- Health aspects, Pharmaceutical industry -- Health aspects, Research and development, General interest, News, opinion and commentary, Cresemba (Medication) -- Health aspects
Abstract

New York City: Pfizer, Inc. has issued the following press release: Pfizer Inc. (NYSE: PFE)and Basilea Pharmaceutica Ltd. (SIX:BSLN), an international biopharmaceutical company specializing in the research and development of [...]

Published
2017

47. United States : Pfizer Receives Exclusive Commercialization Rights in Europe for CRESEMBA, a Novel Treatment for Potentially Life-Threatening Fungal Infections Among Immunocompromised Patients

Subjects
Pfizer Inc., Immunocompromised host -- Care and treatment -- Health aspects, Mycoses -- Care and treatment -- Health aspects, Antifungal agents -- Health aspects, Infection -- Care and treatment -- Health aspects, Industrial research -- United States -- Health aspects, Pharmaceutical industry -- Health aspects, Research and development, Business, international, Cresemba (Medication) -- Health aspects
Abstract

Pfizer Inc and Basilea Pharmaceutica Ltd, an international biopharmaceutical company specializing in the research and development of anti-infective and oncological medicines, today announced they have entered into an agreement whereby [...]

Published
2017

48. Pfizer Receives Exclusive Commercialization Rights in Europe for CRESEMBA, a Novel Treatment for Potentially Life-Threatening Fungal Infections Among Immunocompromised Patients

Subjects
Pfizer Inc., Immunocompromised host -- Care and treatment -- Health aspects, Mycoses -- Care and treatment -- Health aspects, Antifungal agents -- Health aspects, Infection -- Care and treatment -- Health aspects, Industrial research -- United States -- Health aspects, Pharmaceutical industry -- Health aspects, Research and development, General interest, News, opinion and commentary, Cresemba (Medication) -- Health aspects
Abstract

New York City: Pfizer, Inc. has issued the following press release: Pfizer Inc. (NYSE: PFE)and Basilea Pharmaceutica Ltd. (SIX:BSLN), an international biopharmaceutical company specializing in the research and development of [...]

Published
2017

49. Pfizer Receives Exclusive Commercialization Rights in Europe for CRESEMBA, a Novel Treatment for Potentially Life-Threatening Fungal Infections Among Immunocompromised Patients

Subjects
Pfizer Inc., Immunocompromised host -- Care and treatment -- Health aspects, Mycoses -- Care and treatment -- Health aspects, Antifungal agents -- Health aspects, Infection -- Care and treatment -- Health aspects, Industrial research -- United States -- Health aspects, Pharmaceutical industry -- Health aspects, Research and development, General interest, News, opinion and commentary, Cresemba (Medication) -- Health aspects
Abstract

New York City: Pfizer, Inc. has issued the following press release: Pfizer Inc. (NYSE: PFE)and Basilea Pharmaceutica Ltd. (SIX:BSLN), an international biopharmaceutical company specializing in the research and development of [...]

Published
2017

50. Pfizer Receives Exclusive Commercialization Rights in Europe for CRESEMBA, a Novel Treatment for Potentially Life-Threatening Fungal Infections Among Immunocompromised Patients

Subjects
Pfizer Inc. -- International marketing, Mycoses -- Care and treatment -- Health aspects, Antifungal agents -- International marketing -- Health aspects, Infection -- Care and treatment -- Health aspects, Industrial research -- United States -- Health aspects, Pharmaceutical industry -- International marketing -- Health aspects, Research and development, General interest, News, opinion and commentary, Cresemba (Medication) -- International marketing -- Health aspects
Abstract

New York, NY: Pfizer has issued the following press release: 'We believe our well established global presence together with our deep knowledge of infectious diseases will enable us to meaningfully [...]

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results